MARSHALL WACE, LLP

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in NTLA

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$2,776,198

+$1,014,411 QoQ

Shares Held

164,078

+19.4% QoQ

Ownership

0.117%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#77

of 330 holders

Holding Since

Dec 2020

12 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. NTLA ranks #128 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	543,897	$270,169,956
2	INCY	Incyte Corp	1,310,154	$148,519,056
3	RPRX	Royalty Pharma plc	2,450,669	$137,409,009
4	SYRE	Spyre Therapeutics, Inc.	991,693	$88,042,503
5	ALNY	Alnylam Pharmaceuticals, Inc.	259,799	$78,207,292
6	TVTX	Travere Therapeutics, Inc.	1,333,207	$75,739,488
7	MANE	Veradermics, Inc	585,560	$71,988,746
8	DFTX	Definium Therapeutics, Inc.	1,298,946	$61,102,419

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,776,198	164,078	+19.4%	Shares	Other	2026-08-13
2026-03-31	$1,761,787	137,425	+44.1%	Shares	Other	2026-05-15
2024-12-31	$1,111,651	95,339	-71.6%	Shares	Other	2025-02-13
2024-03-31	$9,227,074	335,408	-62.3%	Shares	Other	2024-05-15
2023-12-31	$27,151,284	890,498	+128.9%	Shares	Other	2024-02-14
2022-12-31	$13,574,791	389,074	+5157.8%	Shares	Other	2023-02-14
2022-09-30	$414,104	7,400	-26.9%	Shares	Other	2022-11-14
2022-06-30	$524,017	10,124	-90.5%	Shares	Other	2022-08-15
2022-03-31	$7,725,983	106,316	+42.2%	Shares	Other	2022-05-16
2021-06-30	$12,101,801	74,744	+401.3%	Shares	Sole	2021-08-13
2021-03-31	$1,196,521	14,909	+10.7%	Shares	Sole	2021-05-17
2020-12-31	$732,550	13,466	—	Shares	Sole	2021-02-16
No filing history on record for this holder in this stock.